Anamorelin for patients with cancer cachexia: An integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials

The Lancet Oncology

Volumn 16, Issue 1, 2015, Pages 108-116

  Garcia, José M ^a   Boccia, Ralph V ^b   Graham, Charles D ^c   Yan, Ying ^d   Duus, Elizabeth Manning ^d   Allen, Suzan ^d   Friend, John ^d  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c Charleston Cancer Center   (United States)

^d Helsinn Therapeutics (US) Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAMORELIN; PLACEBO; ANABOLIC AGENT; APPETITE STIMULANT; HYDRAZINE DERIVATIVE; OLIGOPEPTIDE;

ADULT; AGED; ARTICLE; ASTHENIA; BENIGN TUMOR; BODY MASS; BREAST DISEASE; CACHEXIA; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSPNEA; FATIGUE; FEMALE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; INFECTION; INFESTATION; INJURY; INTOXICATION; KIDNEY DISEASE; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY (TOPIC); MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROCEDURAL SITE REACTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; SKIN DISEASE; SOFT TISSUE DISEASE; THORAX DISEASE; TREATMENT OUTCOME; URINARY TRACT DISEASE; UROGENITAL TRACT DISEASE; VASCULAR DISEASE; WEIGHT REDUCTION; ANALYSIS OF VARIANCE; BODY COMPOSITION; COMPLICATION; DRUG EFFECTS; MIDDLE AGED; MUSCLE STRENGTH; NEOPLASM; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; REGRESSION ANALYSIS; TIME; UNITED STATES; VERY ELDERLY; WEIGHT GAIN; YOUNG ADULT;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; AGED, 80 AND OVER; ANABOLIC AGENTS; ANALYSIS OF VARIANCE; APPETITE STIMULANTS; BODY COMPOSITION; CACHEXIA; CLINICAL TRIALS, PHASE II AS TOPIC; FEMALE; HUMANS; HYDRAZINES; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; MUSCLE STRENGTH; NEOPLASMS; OLIGOPEPTIDES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; WEIGHT GAIN; YOUNG ADULT;

EID: 84926127858     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)71154-4     Document Type: Article

References (36)

1. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011, 12:489-495.
2. von Haehling S, Anker SD Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle 2010, 1:1-5.
3. Ross PJ, Ashley S, Norton A, et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?. Br J Cancer 2004, 90:1905-1911.
4. Aapro M, Arends J, Bozzetti F, et al. Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force. Ann Oncol 2014, 25:1492-1499.
5. Sattler F, Bhasin S, He J, et al. Testosterone threshold levels and lean tissue mass targets needed to enhance skeletal muscle strength and function: the HORMA trial. J Gerontol A Biol Sci Med Sci 2011, 66:122-129.
6. Kilgour RD, Vigano A, Trutschnigg B, Lucar E, Borod M, Morais JA Handgrip strength predicts survival and is associated with markers of clinical and functional outcomes in advanced cancer patients. Support Care Cancer 2013, 21:3261-3270.
7. Macciò A, Madeddu C, Mantovani G Current pharmacotherapy options for cancer anorexia and cachexia. Expert Opin Pharmacother 2012, 13:2453-2472.
8. Kumar NB, Kazi A, Smith T, et al. Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. Curr Treat Options Oncol 2010, 11:107-117.
9. Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2013, 3. CD004310.
10. Dev R, Del Fabbro E, Bruera E Association between megestrol acetate treatment and symptomatic adrenal insufficiency with hypogonadism in male patients with cancer. Cancer 2007, 110:1173-1177.
11. Garcia JM, Polvino WJ Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist 2007, 12:594-600.
12. Murphy MG, Plunkett LM, Gertz BJ, et al. MK-0677, an orally active growth hormone secretagogue reverses diet-induced catabolism. J Clin Endocrinol Metab 1998, 83:320-325.
13. Vestergaard ET, Djurhuus CB, Gjedsted J, et al. Acute effects of ghrelin administration on glucose and lipid metabolism. J Clin Endocrinol Metab 2008, 93:438-444.
14. Jatoi A, Daly BD, Hughes VA, Dallal GE, Kehayias J, Roubenoff R Do patients with nonmetastatic non-small cell lung cancer demonstrate altered resting energy expenditure?. Ann Thorac Surg 2001, 72:348-351.
15. Wallenius K, Wallenius V, Sunter D, Dickson SL, Jansson JO Intracerebroventricular interleukin-6 treatment decreases body fat in rats. Biochem Biophys Res Commun 2002, 293:560-565.
16. Lyngsø D, Simonsen L, Bülow J Metabolic effects of interleukin-6 in human splanchnic and adipose tissue. J Physiol 2002, 543:379-386.
17. Guillory B, Splenser A, Garcia J The role of ghrelin in anorexia-cachexia syndromes. Vitam Horm 2013, 92:61-106.
18. Currow DC, Abernethy AP Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome. Future Oncol 2014, 10:789-802.
19. Pietra C, Takeda Y, Tazawa-Ogata N, et al. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile. J Cachexia Sarcopenia Muscle 2014, 5:329-337.
20. Garcia JM, Friend J, Allen S Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer 2013, 21:129-137.
21. Garcia JM, Polvino WJ Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res 2009, 19:267-273.
22. Gale CR, Martyn CN, Cooper C, Sayer AA Grip strength, body composition, and mortality. Int J Epidemiol 2007, 36:228-235.
23. Chang VT, Hwang SS, Feuerman M Validation of the Edmonton Symptom Assessment Scale. Cancer 2000, 88:2164-2171.
24. Blum D, Stene GB, Solheim TS, et al. Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model: a study based on data from an international multicentre project (EPCRC-CSA). Ann Oncol 2014, 25:1635-1642. Euro-Impact.
25. Tsai S Importance of lean body mass in the oncologic patient. Nutr Clin Pract 2012, 27:593-598.
26. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 2008, 149:601-611.
27. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004, 89:2085-2098.
28. Das SK, Eder S, Schauer S, et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science 2011, 333:233-238.
29. Ali S, Chen JA, Garcia JM Clinical development of ghrelin axis-derived molecules for cancer cachexia treatment. Curr Opin Support Palliat Care 2013, 7:368-375.
30. Costelli P, Muscaritoli M, Bossola M, et al. IGF-1 is downregulated in experimental cancer cachexia. Am J Physiol Regul Integr Comp Physiol 2006, 291:R674-R683.
31. Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 2009, 124:2416-2429.
32. Han J, Jogie-Brahim S, Harada A, Oh Y Insulin-like growth factor-binding protein-3 suppresses tumor growth via activation of caspase-dependent apoptosis and cross-talk with NF-κB signaling. Cancer Lett 2011, 307:200-210.
33. Wolf RF, Ng B, Weksler B, Burt M, Brennan MF Effect of growth hormone on tumor and host in an animal model. Ann Surg Oncol 1994, 1:314-320.
34. Hiura Y, Takiguchi S, Yamamoto K, et al. Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study. Cancer 2012, 118:4785-4794.
35. Northrup R, Kuroda K, Duus EM, et al. Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model. Support Care Cancer 2013, 21:2409-2415.
36. Temel J, Currow D, Fearon K, et al. Anamorelin for the treatment of cancer anorexia-cachexia in NSCLC: results from the phase 3 studies ROMANA 1 and 2. Ann Oncol 2014, 25(suppl 5). abstr 14830_PR.